Original article
There is no legal obligation for health services research under the AMNOG. Nevertheless, health services research is becoming increasingly important even in the era of AMNOG. This is particularly evident in light of the discussion surrounding benefit assessments in the area of the so-called existing market. The term "existing market" describes active substances that were approved before 2011 and still enjoy data protection. This article uses individual […]
01.02.2012
Less centralism, more regionalism – these were the core demands of the board of the Bavarian Association of Statutory Health Insurance Physicians (KVB) for the Statutory Health Insurance Care Structure Act, which came into force at the beginning of 2012. Dr. […] explains how the KVB intends to implement these requirements and what the future design of outpatient care in Bavaria should look like – namely, one that is as individualized as possible and does justice to regional peculiarities.
01.02.2012
Prof. Dr. Holger Pfaff and Prof. Dr. Sebastian Harder in the cover interview
01.12.2011
Dr. Maximilian Gaßner, President of the Federal Insurance Office (BVA) in the MVF cover interview
01.10.2011
Outpatient care for CHD patients with elevated cholesterol levels
01.10.2011
The federal government is planning (as it does annually) a reform of the fifth book of the Social Code. Among other things, the plan for 2011 is to revise the planning of needs for contracted physicians. Regional working groups will be formed for this purpose. They will be composed of local government representatives, decision-makers from health insurance funds, associations of statutory health insurance physicians, medical associations, hospital operators, and patient representatives. One of the key goals of the proposed new regulations is […]
16.04.2011
Many scientific innovations are developed in the field of basic research and then, based on the results of in-vitro research, are so solidly processed through small animal experiments that the path to applying these processes to humans is cleared. Further clinical research deals with measuring the effect of the therapeutic procedure and the side effects and at the same time lays the foundation for the approval procedures of the relevant authorities in North America and Europe. In order to be able to measure the effectiveness of therapeutic procedures, special patient groups are often put together in order to measure the effect of the new procedure/medication on a placebo procedure or on other, often older, medications or medical procedures/procedures in prospective randomized studies. A fundamental bias in these studies is often a strictly selected patient population that only slightly corresponds to the overall “real world” population addressed under field conditions.
07.02.2011
Essentially, health insurance companies could be extremely exciting marketing organizations. There are hardly any companies in other industries that fundamentally offer a similar range of product options, given the number of over 15,000 ICDs. However, one must first adopt the perspective of care management to even recognize these opportunities. The possibility and necessity for this are demonstrated by […]
16.12.2010
Dr. Axel Munte, outgoing CEO of KV Bayern, in the MVF cover interview